Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 6 for:    respicardia

Respicardia, Inc. Pivotal Trial of the remedē System

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Respicardia, Inc.
ClinicalTrials.gov Identifier:
NCT01816776
First received: March 19, 2013
Last updated: April 10, 2017
Last verified: April 2017
  Purpose
The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal medical management, compared to outcomes in randomized control subjects receiving optimal medical management and implanted but inactive remedē® systems.

Condition Intervention
Sleep Apnea, Central
Sleep Disordered Breathing
Heart Failure
Device: Treatment Group (transvenous stimulation of the phrenic nerve)
Device: Control Group (Optimal Medical Therapy)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep Apnea

Resource links provided by NLM:


Further study details as provided by Respicardia, Inc.:

Primary Outcome Measures:
  • Apnea-hypopnea index (AHI) [ Time Frame: 6 months ]
    The primary effectiveness objective of the trial is to demonstrate that the Treatment group achieves an AHI reduction from baseline to 6 months post therapy initiation that is greater than the Control group. The primary effectiveness endpoint will be evaluated by comparing the proportions of subjects in the two study groups that meet the following success criterion: Subject success on the primary AHI endpoint is defined as a subject achieving a 50% or greater reduction in AHI from baseline to 6 months post-therapy initiation visit.

  • Primary Safety Endpoint [ Time Frame: 12 months ]
    Freedom from serious adverse events (SAEs) associated with the implant procedure, the remede System, or the delivered therapy at 12 months post therapy initiation visit. Since all randomized subjects are scheduled to receive the remede system there is no formal test of hypotheses comparing freedom from SAEs between study groups.


Secondary Outcome Measures:
  • Central Apnea Index (CAI) [ Time Frame: 6 months ]
    The mean reduction in CAI from baseline to 6 months post-therapy initiation visit in the Treatment group is greater than that in the Control group.

  • Apnea Hypopnea Index (AHI) [ Time Frame: 6 months ]
    The mean reduction in AHI from baseline to 6 months post-therapy initiation visit in the Treatment group is greater than that in the Control group.

  • Arousal Index (ArI) [ Time Frame: 6 months ]
    The mean reduction in ArI from baseline to 6 months post-therapy initiation visit in the Treatment group is greater than that in the Control group.

  • Rapid eye movement sleep (REM) [ Time Frame: 6 months ]
    The mean increase in the percent of sleep time spent in REM from baseline to 6 months post-therapy initiation visit in the Treatment group is greater than that in the Control group.

  • Patient Global Assessment (PGA) [ Time Frame: 6 months ]
    The proportion of subjects with a "moderate" or "marked" improvement in the Patient Global Assessment from baseline to 6 months post-therapy initiation visit in the Treatment group is greater than that in the Control group.

  • Oxygen desaturation index (ODI4) [ Time Frame: 6 months ]
    The mean reduction in the hourly rate of events of oxygen desaturation greater than or equal to 4% (ODI4) from baseline to 6 months post-therapy initiation visit in the Treatment group is greater than that in the Control group.

  • Epworth Sleepiness Scale (ESS) [ Time Frame: 6 months ]
    The mean reduction in ESS from baseline to 6 months post-therapy initiation visit in the Treatment group is greater than that in the Control group.


Estimated Enrollment: 173
Study Start Date: March 2013
Estimated Study Completion Date: December 2017
Primary Completion Date: September 10, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Group
Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
Device: Treatment Group (transvenous stimulation of the phrenic nerve)
device implant, optimal medical therapy and device initiation 1 month post implant.
Other Names:
  • remedē System
  • Transvenous stimulation of the phrenic nerve
Control group
Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
Device: Control Group (Optimal Medical Therapy)
device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
Other Name: Optimal Medical Therapy

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. At least 18 years of age
  2. Central Sleep apnea confirmed by core lab analysis of PSG with EEG within 40 days of scheduled implant:

    • Apnea/Hypopnea Index (AHI) greater than or equal to 20;
    • Central Apnea Index (CAI) at least 50% of all apneas, with at least 30 central apnea events;
    • Oxygen Desaturation Index (OAI) less than or equal to 20% of the total AHI
  3. Medically stable for 30 days prior to all baseline testing (including PSG), i.e., no hospitalizations for illness, no breathing mask-based therapy, and on stable medications and therapies:

    • Stable medications are defined as no changes during this period except for those within a pre-specified sliding scale medication regimen;
    • If the subject has heart failure, the baseline testing (including PSG) should occur at least 6 months after initial diagnosis;
    • If the subject has systolic heart failure, the baseline testing (including PSG) should occur after maximally titrating beta blockers, ACE-I and other medications indicated in the current guidelines (unless contraindicated or not considered medically necessary) and after receiving any indicated device therapy including devices for cardiac resynchronization therapy and/or primary prevention of sudden cardiac death;
    • If subject has a hospitalization or physician visit requiring IV medication between the screening PSG and implant, the subject must be re-screened when stable
  4. Expected to tolerate study procedures in the opinion of the investigator, in particular:

    • Ability to lie down long enough to insert the remede system without shortness of breath and able to tolerate instrumentation for the Polysomnogram/Polygram testing;
    • Expected to tolerate therapy titration and the sensation of therapy, and communicate therapy experience.
  5. In the investigator's opinion, willing and able to comply with all study requirements
  6. Signed the Institutional Revew Board/Medical Ethics Committee approved informed consent (HIPAA authorization in the U.S.)

Exclusion Criteria:

  1. Pacemaker dependent subjects without any physiologic escape rhythm
  2. Suspected inability to place catheter for delivery of stimulation lead (e.g. previously know coagulopathy, distorted anatomy, prior failed pectoral implant, etc.)
  3. Evidence of phrenic nerve palsy
  4. More than 2 previous open chest surgical procedures (e.g., CABG)
  5. Etiology of central sleep apnea known to be caused primarily by pain medication
  6. Documented history of psychosis or severe bipolar disorder
  7. Cerebrovascular accident (CVA) within 12 months of baseline testing
  8. History of idiopathic pulmonary hypertension, World Health Organization Class 1
  9. Limited pulmonary function with either FEV1/FVC less than 65% of predicted value or FVC less than 60% of predicted value
  10. Baseline oxygen saturation less than 92% while awake and on room air after 5 minutes of quiet rest
  11. Anticipated need for chronic oxygen therapy or breathing mask-based therapy for 6 months post therapy initiation visit
  12. Active infection or sepsis within 30 days of enrollment
  13. Currently on renal dialysis or creatinine level greater than 2.5 mg/dL or calculated creatinine clearance equal to or less than 30 ml/min using the Cockcroft-Gault equation
  14. Poor liver function with baseline aspartate transaminase (AST), alanine transaminase (ALT), and/or total bilirubin greater than 3 times the upper limit of normal (per lab normals at each site)
  15. Hemoglobin less than 8 gm/dL
  16. In subjects with heart failure, ACC/AHA Heart Stage D
  17. Within the 3 months prior to baseline testing, any of the following: uncorrected severe valvular stenosis, valve replacement or repair (percutaneous or surgical), myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery, percutaneous coronary intervention (PCI), cardiac ablation, new cardiac resynchronization device or new pacemaker implant
  18. New implantable cardioverter defibrillator or any implantable device generator change-out within 30 days prior to baseline testing or anticipated within the first 6 months of enrollment
  19. Other anticipated surgery or invasive procedure expected to affect ability to perform testing at 6-month post-therapy initiation visit
  20. Unstable angina
  21. Allergy to or intolerant of contrast dye
  22. Pregnancy or of child bearing potential without a negative pregnancy test within 10 days prior to remede system implant
  23. Life expectancy or expected time to transplant or left ventricular assist device of less than 12 months
  24. Currently enrolled or planning to enroll in another study that may conflict with protocol requirements or confound subject results in this trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01816776

  Show 30 Study Locations
Sponsors and Collaborators
Respicardia, Inc.
Investigators
Principal Investigator: Maria Rosa Costanzo, M.D. Midwest Heart Specialists
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Respicardia, Inc.
ClinicalTrials.gov Identifier: NCT01816776     History of Changes
Other Study ID Numbers: Respicardia CR-1005
Study First Received: March 19, 2013
Last Updated: April 10, 2017

Additional relevant MeSH terms:
Heart Failure
Sleep Apnea Syndromes
Sleep Apnea, Central
Heart Diseases
Cardiovascular Diseases
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases

ClinicalTrials.gov processed this record on May 25, 2017